IDH1 and central nervous system cancer: The clinical recognition of EGFR Amp in our IDH-mutant glioma patients was close to previous reports, and the slightly higher frequency may be accounted for by the inclusion of EGFR gene in routine molecular tests for glioma since the publication of cIMPACT-NOW update 3 (Brat et al., 2018).